Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
NCT ID: NCT02290834
Last Updated: 2025-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
200 participants
INTERVENTIONAL
2015-03-31
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Chemotherapy on Cognitive Function in Breast Cancer Patients & Non-Cancer Control Subjects With Optional Sub-Study Research Brain MRI
NCT03137095
Chemotherapy Effect on Brain Structure, Neurophysiology and Psychomotor Behavior in Breast Cancer Patients
NCT02896504
An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors
NCT02515487
Cognitive Changes Associated With Breast Cancer Treatment
NCT00550134
Study of the Effects of Chemotherapy on Memory and Other Mental Functions in Women With Breast Cancer
NCT00260975
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* This study is being done to test for "chemo-brain" in older adults with breast cancer treated with chemotherapy, and to identify people who are most likely to be affected. The investigators will look at thinking abilities and brain images before and after chemotherapy to see if it can help identify people at risk for cognitive side effects of the treatment, and to better understand effects of treatment on brain structure and function.
* The investigators are looking for participants who have either been recently recently diagnosed breast cancer participant or a healthy volunteer.
* What is involved in the study:
* Memory and Thinking Tests
* Imaging: Either MRI/or MRI and PET Scans
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ARM 1
Breast cancer patients treated with chemotherapy
* Cognitive, functional and subjective assessments (Pre and Post Treatment)
* Imaging (Pre and Post Treatment)
* Magnetic Resonance Imaging (MRI) Scan
* Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan
Cognitive, functional and subjective assessments
Cognitive and functional assessments
MRI
Magnetic Resonance Imaging (MRI) Scan
PET Scan
Positron Emission Tomography (PET) Scan
ARM 2
Non-treated breast cancer patient control
* Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later
* Imaging (Post Enrollment and at 8-14 months later)
* Magnetic Resonance Imaging (MRI) Scan
* Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan
Cognitive, functional and subjective assessments
Cognitive and functional assessments
MRI
Magnetic Resonance Imaging (MRI) Scan
PET Scan
Positron Emission Tomography (PET) Scan
ARM 3
Healthy control subjects
* Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later
* Imaging (Post Enrollment and at 8-14 months later)
* Magnetic Resonance Imaging (MRI) Scan
* Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan
Cognitive, functional and subjective assessments
Cognitive and functional assessments
MRI
Magnetic Resonance Imaging (MRI) Scan
PET Scan
Positron Emission Tomography (PET) Scan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cognitive, functional and subjective assessments
Cognitive and functional assessments
MRI
Magnetic Resonance Imaging (MRI) Scan
PET Scan
Positron Emission Tomography (PET) Scan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must meet the following criteria on screening examination to be eligible to participate in the behavioral +/- imaging components of study
* New diagnosis histologically confirmed invasive breast cancer
* Treatment plan to include chemotherapy
* Female subjects age ≥ 60 years.
* Life expectancy ≥ 1 year
* Karnofsky Performance Score (KPS) ≥ 80
* Ability to understand and the willingness to sign a written informed consent document.
* Non-treated breast cancer patient controls- Group 2 (control group)
* Participants must meet the following criteria on screening examination to be eligible to participate in the behavioral +/- imaging components of study:
* New diagnosis histologically confirmed invasive breast cancer
* Treatment plan does not include chemotherapy
* Age ≥ 60 years.
* Life expectancy ≥ 1 year
* Karnofsky Performance Score (KPS) ≥ 80
* Ability to understand and the willingness to sign a written informed consent document.
* Healthy control subjects- Group 3 (control group)
* Participants must meet the following criteria on screening examination to be eligible to participate in the behavioral +/- imaging components of study:
* Age ≥ 60 years.
* Life expectancy ≥ 1 year
* Karnofsky Performance Score (KPS) ≥ 80
* Ability to understand and the willingness to sign a written informed consent document.
* Participants with well-controlled vascular risk factors, such as treated hypertension, treated hyperlipidemia or well-controlled Type II diabetes (glucose levels \<250) may be included.
* Serum Pregnancy Testing: STAT quantitative serum hCG pregnancy testing for all women of childbearing potential. Imaging will not start until and unless the test result returns negative.
Exclusion Criteria
* Participants with clinical or radiographic evidence of metastatic CNS disease
* Subjects with MMSE scores below 24
* Active or history of major psychiatric disorders such as schizophrenia, schizoaffective disorder, major affective disorder in mid-life, or treatment with ECT (Mild depression that is well treated with stable dose of SSRI antidepressants may be allowed).
* Substance abuse within the past 2 years
* Huntington's disease, hydrocephalus or seizure disorder
* Participants with contraindications to MRI (i.e., implanted metal including pacemakers, cerebral spinal fluid shunts, aneurysm clips, artificial heart valves, ear implants or metal/foreign objects in the eyes and those with a history of claustrophobia), injuries to the eyes with metal without X-ray documentation that metal was removed
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael W Parsons
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Parsons, PhD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Massachusetts General Hospital
Boston, Massachusetts, United States
Massachusetts General Hospital/North Shore Cancer Center
Salem, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-217
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.